Boston, MA – SARS-CoV-2 accounted for 1 in 6 cases of sepsis during the first 33 months of the COVID-19 pandemic, highlighting the importance of viral sepsis, according to a new study led by researchers at the Harvard Pilgrim Health Care Institute. The study comes at the end of Sepsis Awareness Month, a timely reminder of the importance of sepsis research.
 

The study, “Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2-Associated Sepsis”, was published on September 29 in JAMA Network Open.

Sepsis is defined as a severe infection that leads to organ failure. It is a leading cause of death, disability, and health care costs. Although most clinicians and researchers equate sepsis with bacterial infection, the COVID-19 pandemic has made it clear that viral infections can be an important cause of sepsis. Few studies, however, have quantified the contribution of viral infections to the overall burden of sepsis and how the outcomes of patients with viral sepsis compare to those with bacterial sepsis.

Our prior research has shown that electronic health record (EHR)-based surveillance using clinical markers of infection and organ dysfunction can provide more accurate estimates of sepsis incidence and outcomes compared to using hospital discharge diagnosis codes, but this method had not previously been applied specifically for sepsis associated with SARS-CoV-2 or other viruses.

- Chanu Rhee, MD, MPH

“Previous efforts to quantify the burden of SARS-CoV-2-associated sepsis have been limited by inconsistent definitions and under-recognition of viral sepsis,” said senior author Chanu Rhee, Harvard Medical School Associate Professor of Population Medicine at the Harvard Pilgrim Health Care Institute.  “Our prior research has shown that electronic health record (EHR)-based surveillance using clinical markers of infection and organ dysfunction can provide more accurate estimates of sepsis incidence and outcomes compared to using hospital discharge diagnosis codes, but this method had not previously been applied specifically for sepsis associated with SARS-CoV-2 or other viruses.” 

The study researchers performed a retrospective cohort study using EHR data for all adults admitted to five Massachusetts hospitals between March 2020 and November 2022. The team quantified the incidence and in-hospital mortality for sepsis associated with SARS-CoV-2 infections using clinical criteria adapted from CDC’s sepsis surveillance definition that incorporated positive SARS-CoV-2 tests and clinical signs of organ dysfunction. They found that approximately 1 in 6 cases of sepsis were associated with SARS-CoV-2 during this period. The mortality rate for patients with SARS-CoV-2-associated sepsis was very high initially—33% over the first three months of the pandemic—but declined over time and eventually became similar to the mortality rate for presumed bacterial sepsis, a rate of about 14.5% that remained stable throughout the study period.  The researchers also confirmed their electronic surveillance definition accurately identified cases of viral sepsis caused by SARS-CoV-2 infections using detailed medical record reviews.

We hope our findings will highlight that sepsis is not a 'one-size-fits-all' entity, but one that requires clinicians to tailor their diagnosis and treatment strategy to each patient’s syndrome and probable pathogen.

- Claire Shappell, MD, MPH

“Our study draws attention to the high burden and poor outcomes associated with viral sepsis, while also demonstrating the utility of using EHR-based algorithms to conduct surveillance for both viral and bacterial sepsis”, says Claire Shappell, a former research fellow at the Harvard Pilgrim Health Care Institute and lead author of the study. Dr. Shappell, now a Harvard Medical School Instructor of Medicine in the Division of Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital, adds, “Current sepsis treatment protocols often presume sepsis is caused by bacteria and suggest treating all patients with sepsis with broad-spectrum antibiotics and intravenous fluids. We hope our findings will highlight that sepsis is not a “one-size-fits-all” entity, but one that requires clinicians to tailor their diagnosis and treatment strategy to each patient’s syndrome and probable pathogen.” 

About
The Harvard Pilgrim Health Care Institute's Department of Population Medicine is a unique collaboration between Harvard Pilgrim Health Care and Harvard Medical School. Created in 1992, it is the first appointing medical school department in the United States based in a health plan. The Institute focuses on improving health care delivery and population health through innovative research and education, in partnership with health plans, delivery systems, and public health agencies. Point32Health is the parent company of Harvard Pilgrim Health Care and Tufts Health Plan.

More Information
Shappell CN, Klompas M, Chan C, et al. Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2–Associated Sepsis. JAMA Netw Open. 2023;6(9):e2335728. doi:10.1001/jamanetworkopen.2023.35728